These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Novel approaches for the treatment of HIV. Arroyo HT Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450 [TBL] [Abstract][Full Text] [Related]
9. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections. Bartnof HS BETA; 1998 Apr; ():49-56. PubMed ID: 11365269 [TBL] [Abstract][Full Text] [Related]
10. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR; Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858 [TBL] [Abstract][Full Text] [Related]
11. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV]. Bayonne Kombo ES; Gathse A Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355 [No Abstract] [Full Text] [Related]
12. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061 [TBL] [Abstract][Full Text] [Related]
13. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM; N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087 [TBL] [Abstract][Full Text] [Related]
14. A new HAART on the horizon says the proof is in the potency. AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218 [TBL] [Abstract][Full Text] [Related]
15. 1592 (abacavir): do not rechallenge after hypersensitivity reaction. James JS AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916 [TBL] [Abstract][Full Text] [Related]
16. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR; J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261 [TBL] [Abstract][Full Text] [Related]
17. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA; N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850 [TBL] [Abstract][Full Text] [Related]
18. [Toxic epidermal necrolysis associated with abacavir]. Montero M; García-Gibert L; Giménez-Arnau AM; Knobel H Enferm Infecc Microbiol Clin; 2005 Apr; 23(4):247. PubMed ID: 15826554 [No Abstract] [Full Text] [Related]
19. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir. Anderson RD Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514 [TBL] [Abstract][Full Text] [Related]
20. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients. Bellagamba R; Tommasi C; De Marco M; Narciso P J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915 [No Abstract] [Full Text] [Related] [Next] [New Search]